Swertisin
Based on 2 publication(s) in Google Scholar
Swertisin is an oral adenosine A1 receptor antagonist and an SGLT2 inhibitor. Swertisin has anti-diabetic, antioxidant properties, inhibits HBV, and improves cognitive and memory impairments in mice.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.54%
- CAS No.: 6991-10-2
- Formule: C22H22O10
- Masse moléculaire:446.40
-
Stockage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
GPCR/G Protein Compound Library
HY-L006
-
Immunology/Inflammation Compound Library
HY-L007
-
Membrane Transporter/Ion Channel Compound Library
HY-L011
-
Natural Product Library
HY-L021
-
Antiviral Compound Library
HY-L027
-
Small Molecule Immuno-Oncology Compound Library
HY-L031
-
Antioxidant Compound Library
HY-L037
-
Anti-diabetic Compound Library
HY-L040
-
Glycoside Compound Library
HY-L042
-
Medicine Food Homology Compound Library
HY-L055
-
Phenols Library
HY-L057
-
Orally Active Compound Library
HY-L061
-
Neurotransmitter Receptor Compound Library
HY-L062
-
Traditional Chinese Medicine Active Compound Library
HY-L065
-
Flavonoids Library
HY-L068
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Anti-Parkinson's Disease Compound Library
HY-L085
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Anti-Obesity Compound Library
HY-L087
-
Antiviral Traditional Chinese Medicine Active Compound Library
HY-L113
-
Anti-inflammatory Traditional Chinese Medicine Active Compound Library
HY-L114
-
Plant-Sourced Natural Product Library
HY-L115
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product Library Plus
HY-L021P
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
Anti-Fibrosis Compound Library
HY-L185
-
Miao Ethnicity Medicine Compound Library
HY-L190
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library
HY-L209
-
Diarrhea-Related Traditional Chinese Medicine Active Compound Library
HY-L224
-
Mongolian Medicine Compound Library
HY-L238
-
Tonifying Traditional Chinese Medicine Monomer Compound Library
HY-L246
-
Lactylation Compound Library
HY-L249
-
Mass Spectrometry Natural Product Library
HY-L262
Publications Citing Use of MedChemExpress (MCE) Swertisin
MoreVoir tous les produits spécifiques à Isoform Adenosine Receptor
More
Activité biologique
|
SGLT2 |
Swertisin (7.5 μg/mL, 0-12 h) inhibits glucose uptake in HEK293 cells and reduces the expression of SGLT2[2].
Swertisin (0.2-5 μM, 6-12 days) suppresses levels of HBsAg, HBeAg and HBV DNA in HepG2.2.15 and HBV-infected HepG2-NTPC cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HEK293T
-
Concentration:7.5 μg/mL
-
Incubation Time:0, 4, 8, 12 h
-
Result:Decreased the expression of SGLT2 in a dose-dependent manner, while PKC expression was upregulated.
-
Cell Line:HepG2.2.15, HepG2-NTPC
-
Concentration:0.2, 0.5, 1, 2, 5 μM
-
Incubation Time:7 days; 6, 9, 12 days
-
Result:Reduced HBsAg and HBeAg levels.
Swertisin (2.5 mg/kg, intraperitoneally, once daily, days) reduces the expression of SGLT2 in mouse kidney tissue and can quickly lower blood sugar[2].
Swertisin (0-10 mg/kg, intraperitoneally, every other day, 20 days) significantly inhibits HBV replication in a HBV transgenic mouse model[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Mice induced by MK801 (HY-15084B)[1]
-
Dosage:30 mg/kg; single dose
-
Administration:Oral gavage (p.o.)
-
Result:Alleviated the pre-pulse inhibition defect, reversed memory recognition impairment, and the elevated phosphorylation levels of Akt and GSK-3β signaling molecules in the prefrontal cortex restore normal function.
-
Animal Model:BALB/c mice induced by STZ (HY-13753)[2]
-
Dosage:2.5 mg/kg; daily; 15 days
-
Administration:Intraperitoneal injection (i.p.)
-
Result:Improved overall glucose homeostasis, reduced SGLT2 expression in renal tissue, reduced PKC expression, and had a rapid hypoglycemic effect.
-
Animal Model:HBV transgenic mice[3]
-
Dosage:0, 5, 10 mg/kg; every other day; 20 days
-
Administration:Intraperitoneal injection (i.p.)
-
Result:Showed that there was no significant weight loss, no significant changes in serum ALT and AST levels, and reduced serum HBsAg and HBeAg levels.
Chemical Information
-
CAS No. 6991-10-2
-
Appearance Solid
-
Masse moléculaire 446.40
-
Formule C22H22O10
-
Color Light yellow to yellow
-
SMILES
O=C1C=C(C2=CC=C(O)C=C2)OC3=CC(OC)=C([C@H]4[C@@H]([C@H]([C@@H]([C@@H](CO)O4)O)O)O)C(O)=C13
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
J Ethnopharmacol
Cornus officinalis var. koreana Kitam extracts alleviate cadmium-induced renal fibrosis by targeting matrix metallopeptidase 9. [Abstract]2024 May 10:325:117824. PMID: 38278375 -
Vet Microbiol
The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]2026 May:316:110992. PMID: 41865607
Solvant et solubilité
DMSO : 50 mg/mL (112.01 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.25 mg/mL (2.80 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.25 mg/mL (2.80 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (280 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Oh HK, et al. Swertisin ameliorates pre-pulse inhibition deficits and cognitive impairment induced by MK-801 in mice. J Psychopharmacol. 2017 Feb;31(2):250-259. [Content Brief]
[2]. Gurprit Bhardwaj, et al. Swertisin, a novel SGLT2 inhibitor, with improved glucose homeostasis for effective diabetes therapy. Arch Biochem Biophys. 2021 Oct 15:710:108995. [Content Brief]
[3]. Hong-Yan Xu, et al. Anti-hepatitis B virus activity of swertisin isolated from Iris tectorum Maxim. J Ethnopharmacol. 2020 Jul 15:257:112787. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2401 mL | 11.2007 mL | 22.4014 mL | 56.0036 mL |
| 5 mM | 0.4480 mL | 2.2401 mL | 4.4803 mL | 11.2007 mL | |
| 10 mM | 0.2240 mL | 1.1201 mL | 2.2401 mL | 5.6004 mL | |
| 15 mM | 0.1493 mL | 0.7467 mL | 1.4934 mL | 3.7336 mL | |
| 20 mM | 0.1120 mL | 0.5600 mL | 1.1201 mL | 2.8002 mL | |
| 25 mM | 0.0896 mL | 0.4480 mL | 0.8961 mL | 2.2401 mL | |
| 30 mM | 0.0747 mL | 0.3734 mL | 0.7467 mL | 1.8668 mL | |
| 40 mM | 0.0560 mL | 0.2800 mL | 0.5600 mL | 1.4001 mL | |
| 50 mM | 0.0448 mL | 0.2240 mL | 0.4480 mL | 1.1201 mL | |
| 60 mM | 0.0373 mL | 0.1867 mL | 0.3734 mL | 0.9334 mL | |
| 80 mM | 0.0280 mL | 0.1400 mL | 0.2800 mL | 0.7000 mL | |
| 100 mM | 0.0224 mL | 0.1120 mL | 0.2240 mL | 0.5600 mL |
Swertisin Related Classifications
HY-N2189 Related Classifications
Powered by Bioz